Search research articles
Contact Us
Filters
Showing results (31-40 of 34) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 34 results.
The Journal of Biological Chemistry
|
January 5, 1988
cDNA, deduced polypeptide structure and chromosomal assignment of human pulmonary surfactant proteolipid, SPL(pVal)
S W Glasser, T R Korfhagen, T E Weaver, et al.
International Dental Journal
|
August 1, 1996
The community care model of the Intercountry Centre for Oral Health at Chiangmai, Thailand
T Anumanrajadhon, S Rajchagool, P Nitisiri, et al.
Journal of Viral Hepatitis
|
April 7, 2018
Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir
G Schnell, R Tripathi, J Beyer, et al.
Journal of Viral Hepatitis
|
August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S D Shafran, D Shaw, M Charafeddine, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 34) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 34 results.
The Journal of Biological Chemistry
|
January 5, 1988
cDNA, deduced polypeptide structure and chromosomal assignment of human pulmonary surfactant proteolipid, SPL(pVal)
S W Glasser, T R Korfhagen, T E Weaver, et al.
International Dental Journal
|
August 1, 1996
The community care model of the Intercountry Centre for Oral Health at Chiangmai, Thailand
T Anumanrajadhon, S Rajchagool, P Nitisiri, et al.
Journal of Viral Hepatitis
|
April 7, 2018
Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir
G Schnell, R Tripathi, J Beyer, et al.
Journal of Viral Hepatitis
|
August 24, 2017
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III)
S D Shafran, D Shaw, M Charafeddine, et al.
Page
of 4